跳至主要内容
临床试验/NCT05878405
NCT05878405已完成3 期

Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer: An Open-Label, Non-Randomized, Controlled Study

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2023年6月6日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Mayo Clinic
入组人数
49
试验地点
2
主要终点
Change in oral pain

研究概览

简要总结

This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer. Using methlylene blue mouthwash may improve oral pain in patients with oral mucositis related to cancer and/or cancer treatments compared to usual standard of care.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Active cancer diagnosis
  • Admitted to the inpatient setting
  • Pain related to oral mucositis
  • Experiencing oropharyngeal pain
  • Able to provide informed consent

排除标准

  • Pediatric age (under 18 years old)
  • Pregnant or nursing women
  • Any contraindication to methylene blue including severe hypersensitivity to methylene blue and patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia

结局指标

主要结局

Change in oral pain

时间窗: Baseline, 3 days

Pain will be assessed using the standard institutional numeric rating scale where pain level is quantified on a scale of 0 (no pain) to 10 (worst possible pain) pre- and post-intervention (3 times daily for 3 days). Last collected scores will be compared to baseline.

次要结局

  • Change in the amount of oral intake(Baseline, 3 days)
  • Change in the amount of daily requirements of oral morphine equivalents(Baseline, 3 days)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验